Last reviewed · How we verify

NCT04634188

Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study

Completed Last updated 18 November 2020
What this trial tests

trial testing Procalcitonin in Brain Tumor in 35 participants. Completed in 1 October 2020.

Timeline
1 January 2020
Primary endpoint
1 September 2020
1 October 2020

Quick facts

Lead sponsorUniversitas Sumatera Utara
StatusCompleted
Study typeOBSERVATIONAL
Enrollment35
Start date1 January 2020
Primary completion1 September 2020
Estimated completion1 October 2020
Sites1 location across Indonesia

Drugs / interventions tested

Conditions studied

Sponsor

Universitas Sumatera Utara — full company profile →

Who can join

Adults 18 to 70, any sex, with Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then categorized according to the variables above and analyzing to measure its significance

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Role and value of inflammatory markers in brain tumors: A case controlled study.
    Dharmajaya R, Sari DK. · · 2021 · cited 18× · PMID 33659053 · DOI 10.1016/j.amsu.2021.01.055

Verify or expand the search:

Other trials of Procalcitonin

Trials testing the same drug.

Other recruiting trials for Brain Tumor

Currently open trials in the same condition.

Other Universitas Sumatera Utara trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04634188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing